OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

被引：3

作者：

Robson, Mark E. ^{[1
]}

Im, Seock-Ah ^{[2
]}

Senkus, Elzbieta ^{[3
]}

Xu, Binghe ^{[4
]}

Domchek, Susan ^{[5
]}

Masuda, Norikazu ^{[6
]}

Delaloge, Suzette ^{[7
]}

Li, Wei ^{[8
]}

Tung, Nadine ^{[9
]}

Armstrong, Anne ^{[10
]}

Wu, Wenting ^{[11
]}

Goessl, Carsten ^{[11
]}

Runswick, Sarah ^{[12
]}

Conte, Pierfranco ^{[13
,14
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Med Univ Gdansk, Gdansk, Poland

[4] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[5] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA

[6] Natl Hosp Org, Osaka Natl Hosp, Osaka, Japan

[7] Inst Gustave Roussy, Villejuif, France

[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China

[9] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA

[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[11] AstraZeneca, Gaithersburg, MD USA

[12] AstraZeneca, Macclesfield, Cheshire, England

[13] Univ Padua, Padua, Italy

[14] Ist Oncol Veneto IRCCS, Padua, Italy

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-CT038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT038

引用

页数：2

共 50 条

[1] OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Robson, M. E.
Tung, N.
Conte, P.
Im, S-A
Senkus, E.
Xu, B.
Masuda, N.
Delaloge, S.
Li, W.
Armstrong, A.
Wu, W.
Goessl, C.
Runswick, S.
Domchek, S. M.
ANNALS OF ONCOLOGY, 2019, 30 (04) : 558 - 566
[2] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
Robson, Mark E.
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Delaloge, Suzette
Li, Wei
Tung, Nadine M.
Armstrong, Anne
Wu, Wenting
Goessl, Carsten Dietrich
Runswick, Sarah
Conte, Pier Franco
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
[3] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
Robson, Mark E.
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Delaloge, Suzette
Li, Wei
Tung, Nadine M.
Armstrong, Anne
Wu, Wenting
Goessl, Carsten Dietrich
Runswick, Sarah
Conte, Pier Franco
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Robson, Mark
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Domchek, Susan
Masuda, Norikazu
Delaloge, Suzette
Li, Wei
Tung, Nadine
Armstrong, Anne
Bannister, Wendy
Goessl, Carsten
Allen, Allison
Conte, Pierfranco
CANCER RESEARCH, 2020, 80 (04)
[5] OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Robson, Mark E.
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Delaloge, Suzette
Tung, Nadine
Armstrong, Anne
Dymond, Mike
Fielding, Anitra
Allen, Allison
Conte, Pierfranco
EUROPEAN JOURNAL OF CANCER, 2023, 184 : 39 - 47
[6] Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases
Tung, Nadine M.
Im, Seock-Ah
Senkus-Konefka, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Li, Wei
Armstrong, Anne Caroline
Conte, Pier Franco
Wu, Wenting
Goessl, Carsten Dietrich
Runswick, Sarah
Robson, Mark E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
Domchek, Susan M.
Robson, Mark
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Masuda, Norikazu
Delaloge, Suzette
Li, Wei
Armstrong, Anne
Conte, Pierfranco
Bannister, Wendy
Goessl, Carsten
Runswick, Sarah
Goel, Saurabh
Tung, Nadine
CANCER RESEARCH, 2018, 78 (04)
[8] EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician's choice (TPC) in OlympiAD
Robson, Mark E.
Ruddy, Kathryn Jean
Im, Seock-Ah
Senkus-Konefka, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Li, Wei
Tung, Nadine M.
Armstrong, Anne Caroline
Bannister, Wendy
Goessl, Carsten Dietrich
Degboe, Arnold
Hettle, Robert
Conte, Pier Franco
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice (TPC)
Robson, M.
Ruddy, K. J.
Im, S-A.
Senkus-Konefka, E.
Xu, B.
Domchek, S. M.
Masuda, N.
Delaloge, S.
Li, W.
Tung, N.
Armstrong, A.
Wu, W.
Goessl, C.
Degboe, A.
Conte, P. F.
ANNALS OF ONCOLOGY, 2017, 28
[10] Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).
Meisner, Eleanor
Rollins, Rebecca
Ensor, Joe
Moran, Amber
Woodward, Amanda
Ahn, Eugene R.
Lynch, Cynthia Anne
Citrin, Dennis L.
Hansra, Damien
Aithal, Sramila S.
Ninan, Mary
Nixon, Daniel W.
Zook, Susan
Ali, Siraj Mahamed
Markman, Maurie
Alvarez, Ricardo H.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →